Conditions: Glaucoma Ocular Hypertension
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 93
Healthy volunteers: no

Brief summary:
This efficacy and safety study will evaluate LUMIGAN® RC/ LUMIGAN® .01 (bimatoprost 0.01%) alone compared to TRAVATAN Z® (travoprost 0.004%) and TIMOLOL MALEATE-EX, 0.5%/TIMOLOL GFS 0.5% (timolol 0.5% ophthalmic gel forming solution) in patients who require IOP lowering therapy.

Detailed description:

Arms:
arm 1: Bimatoprost 0.01% and hypromellose 0.3% lubricant eye drops (for masking purposes) each administered to both eyes once daily for 12 weeks. arm 2: Travatan 0.004% and timolol 0.5% each administered to both eyes once daily for 12 weeks.

Interventions: intervention 1: bimatoprost 0.01% intervention 2: travatan 0.004% intervention 3: timolol 0.5% intervention 4: hypromellose 0.3%
Intervention descriptions: intervention 1: Bimatoprost 0.01% administered to both eyes once daily for 12 weeks. intervention 2: Travatan 0.004% administered to both eyes once daily for 12 weeks. intervention 3: Timolol 0.5% administered to both eyes once daily for 12 weeks. intervention 4: Hypromellose 0.3% lubricant eye drops (for masking purposes) administered to both eyes once daily for 12 weeks.

Protocol document: